Scancell Holdings plc (AIM: SCLP), the developer of ImmunoBody and Moditope active immunotherapies to treat cancer, today announces a business ...

Activation of immune blood biomarkers from interferon gamma pathway distinguished long-term survivors (>=2 years) ...

January 13, 2026 - PRESSADVANTAGE - In the highly regulated field of medical device labeling translation, ensuring that ...

SHELTON, CONNECTICUT / ACCESS Newswire / January 13, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a ...

The settlement agreement allows Alvotech and its commercial partners to market and sell the biosimilar as of January 1, 2026 in the United Kingdom and Canada, as well as in Japan (excluding the ...

At 31 October 2025, net liabilities of the Group amounted to £8.4 million (30 April 2025: £3.8 million) and it held cash of £8.6 million (30 April 2025: £16.9 million). R&D tax credits of £3.0 million ...

Jaguar has received the initial $16M payment related to the company's recently executed US out-license agreement for ...

Among the health policy novelties of 2025, a new tool developed by the European Medicines Agency (EMA) is set to harmonise monitoring of medicine shortages across Europe. View on euronews ...

EMA and FDA have jointly issued guiding principles for the safe and responsible use of AI across the medicines life cycle, aiming to harmonize ...

Britain and several other European countries have lost their measles elimination status, the World Health Organization said ...

Otsuka Pharmaceutical, which licensed the antisense oligonucleotide from Ionis, has rights to commercialize it in Europe and Asia.

This is eight fewer than the FDA, which approved 46 novel drugs in 2025 – sneaking in two regulatory decisions during the ...